Former Affiliate Novo Holdings Plans $24M Share Sale After Positive Trial Data
MPLT sits 59% above its 52-week low of $9.1 on elevated volume (4.5× avg).
Summary
Former affiliate Novo Holdings A/S filed a Form 144 to sell 1.6 million shares (~$24M) of MapLight Therapeutics, representing about 3.5% of outstanding shares, shortly after positive Phase 2 trial results.
Key Events · Ownership and Investor Activity · MPLT
-
Novo Holdings Plans $24M Share Sale
Former affiliate Novo Holdings A/S filed a Form 144 to sell 1,600,000 shares of MapLight Therapeutics, with an approximate market value of $24,032,000 based on the filing date price.
-
Sale Represents ~3.5% of Outstanding Shares
The 1.6 million shares to be sold equal about 3.5% of the 45,345,676 shares outstanding, a significant block that could pressure the stock.
-
Timing Follows Positive Phase 2 Data
The filing comes three days after MapLight announced positive Phase 2 ZEPHYR trial results for ML-007C-MA in schizophrenia, a catalyst that boosted the stock price and may have prompted the sale.
-
No Prior Sales by Novo in Past 3 Months
The Form 144 indicates no sales by Novo Holdings in the prior three months, making this the first reported disposition by this holder.
Analysis · MPLT · Life Sciences
Just three days after MapLight Therapeutics announced positive Phase 2 ZEPHYR trial results for ML-007C-MA in schizophrenia—news that lifted the stock—former affiliate Novo Holdings A/S filed to sell 1.6 million shares worth approximately $24 million. The sale represents about 3.5% of outstanding shares and marks the first reported disposition by this holder. Although Novo is no longer an insider, the size and timing following a major catalyst could signal a strategic exit or portfolio rebalancing by a large early investor.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.1% of the 1692 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MPLT was trading at $14.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $597.9M. The 52-week trading range was $9.10 to $40.43. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.